Series A AI companies in Austin

We are redefining scientific possibility with our algorithm-driven technology that produces pristine synthetic DNA molecules, enabling our partners to deliver a new generation of transformative solutions for the health of people and planet.

• Series A
• 57 employees
• Founded 2018

As innovation leader in the field of high-resolution 3D printing,we see it as our mission to upscale nanofabrication.UpNano is a Vienna (Austria) based high-tech company with the focus on development, manufacturing and commercialization of high-resolution 3D-printers. The systems are based on 2-photon-polymerization which offer industry-leading speed and resolution down to 0.2 μm. UpNano is committed to providing customers with a holistic package of hardware, software and optimized printing materials, for the fabrication of polymeric microparts as well as the unique possibility of bioprinting in a native cell environment. Using UpNano’s cutting-edge technology makes it possible to print objects with sizes ranging from the sub-micrometer to the centimeter range and up to 40 mm in height – within times and precision never achieved before. UpNano was founded in September 2018 as a spin off of the TU Wien and has since developed into an established provider of 3D printing systems for research facilities, universities and businesses worldwide.

• Series A
• 52 employees
• Founded 2018

ViraTherapeutics develops a new class of immunotherapy drugs based on oncolytic (cancer-destroying) viruses. Our patent protected virus is designed to be sa...

• Series A
• 32 employees
• Founded 2013

Phantom Neuro is creating the first minimally invasive peripheral neural interface, the Phantom X. Our technology allows complex electronic systems, like prosthetic limbs, to operate like natural extensions of the human body. We are a group of forward thinking individuals on a mission to help people with function-limiting injuries.

• Series A
• 19 employees
• Founded 2020

YGION Biomedical is an Austrian biotechnology company, dedicated to make individualized cancer immunotherapy a reality. By applying groundbreaking, innovative technologies, we strive to provide better and more effective treatments to cancer patients. Our approach encompasses a targeted activation of the patient’s immune system, promising to elicit a fast, strong, and long-lasting specific immune response with an excellent safety profile. We believe that directing the patient’s immune system specifically against the tumor will provide an opportunity for long-term protection against tumor relapse and metastasis and thus will contribute to an improved success for the treatment of cancer.

• Series A
• 16 employees
• Founded 2022